Biodesix Scores $7.1M For Lung Cancer Tests

Broomfield, Colorado-based Biodexis, a developer of tests for non-small cell lung cancer, said today that it has raised $7.1M in a Series C financing round . The round came from the firm's existing investors, plus another five new investors. According to the company, the new funding will go towards commercialization of its VeriStrat serum proteomic test for guiding treatment of patients with non-small cell lung cancer (NSCLC). Names of the investors were not disclosed. In addition to the new funding, the firm also said it has received $1.4M in grants, from the Qualified Therapeutic Discovery Program, part of the Patient Protection and Affordable Care Act of 2010. The firm said those grants will go towards advancement of six molecular diagnostic programs in oncology and autoimmune disease. More information »